Juno Therapeutics, Inc.
JUNO
JUNO was delisted on the 5th of March, 2018.
157 hedge funds and large institutions have $1.55B invested in Juno Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 52 increasing their positions, 48 reducing their positions, and 26 closing their positions.
22% more capital invested
Capital invested by funds: $1.27B → $1.55B (+$281M)
12% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 26
8% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 48
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1% less funds holding
Funds holding: 159 → 157 (-2)
26% less call options, than puts
Call options by funds: $13.1M | Put options by funds: $17.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$89.5M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$17.9M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$15.9M |
| 4 |
Goldman Sachs
New York
|
+$15.3M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$13.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$33.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.62M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.42M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$3.76M |
| 5 |
Citigroup
New York
|
-$3.64M |
JUNO Hedge Fund Activity: Q1 2017 in Review
157 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q1 2017, worth a combined $1.55B — up 22% from $1.27B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new JUNO positions and 26 closed out — a net gain of 3 holders — while 52 added to existing stakes and 48 trimmed.
The largest buyer was BlackRock, adding an estimated $89.5M. The largest seller was Scopia Capital Management, exiting entirely with an estimated $33.5M sold.
- 157 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q1 2017, down from 159 in Q4 2016.
- Funds reported $1.55B of Juno Therapeutics, Inc. stock for Q1 2017, up 22% quarter-over-quarter.
- 29 funds opened new Juno Therapeutics, Inc. positions in Q1 2017 and 26 closed out, a net change of +3 holders.
- The largest Juno Therapeutics, Inc. buyer in Q1 2017 was BlackRock, an estimated $89.5M added.
- The largest Juno Therapeutics, Inc. seller in Q1 2017 was Scopia Capital Management, an estimated $33.5M sold.
Based on aggregated 13F filings for Q1 2017.